This article is more than 5 years old. Information may no longer be current.

Can-Fite granted patent for IOP-reducing drug candidate

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Patent and Trademark Office has granted Can-Fite BioPharma U.S. patent No. 8,557,790 for an A3 adenosine receptor agonist to reduce IOP, according to a press release.

The patent relates to the use of the drug candidate CF101, an orally bioavailable A3 adenosine receptor agonist drug.

CF101 has demonstrated efficacy and safety in phase 2 clinical studies and is being developed by Can-Fite for dry eye syndrome (phase 3), glaucoma (phase 2) and uveitis (initiating phase 2), according to the release.

Pursuant to a license agreement between Can-Fite and OphthaliX’s wholly owned subsidiary, EyeFite, OphthaliX has exclusive rights to use and develop CF101 for the reduction of IOP in the U.S. until 2030, the release said.